Brookstone Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Brookstone Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.9K	Sell	13,484 -806	-6%	-$1.97K	﹤0.01%	1305
2026 Q1	$30.4K	Buy	+14,290	New	+$34K	﹤0.01%	1197

Other funds holding BDTX

DIM

DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

Brookstone Capital Management's BDTX Position: Q2 2026 in Review

Brookstone Capital Management reduced its Black Diamond Therapeutics (BDTX) stake by 5.6% in Q2 2026, selling an estimated $1.97K and leaving 13,484 shares worth $24.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

Brookstone Capital Management first reported a position in BDTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $30.4K in Q1 2026. 2 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Brookstone Capital Management held 13,484 shares of Black Diamond Therapeutics worth $24.9K as of Q2 2026.
Brookstone Capital Management sold 806 Black Diamond Therapeutics shares in Q2 2026, an estimated $1.97K.
Black Diamond Therapeutics made up ﹤0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #1305 holding.
Brookstone Capital Management first reported a position in Black Diamond Therapeutics in Q1 2026 and has held it in 2 quarters since.
Brookstone Capital Management's Black Diamond Therapeutics position peaked at $30.4K in Q1 2026.
2 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.